PARIS (8 November 2016) — International law firm McDermott Will & Emery advised Dynacure, a new company specialized in rare neuromuscular disorders, on a partnership with Kurma Partners, Indinvest Partners, SATT Conectus and Ionis Pharmaceuticals.
In its first drug discovery program, Dynacure is partnering with Ionis to use Ionis’ innovative antisense platform to develop a new therapeutic approach for treating rare myopathies linked to a target identified by the academic group of Jocelyn Laporte at the IGBMC (Institute of Genetic and Molecular and Cellular Biology), of which Dynacure is a spin-off.
The McDermott Will & Emery team included partner Emmanuelle Trombe assisted by counsel Myrtille Lapuelle and associates Marion Abecassis and Anne Febvre.
With lawyers practicing across the United States and Europe, and in cooperation with MWE China Law Offices, the life sciences team at McDermott provides effective, coordinated counsel on legal issues facing clients worldwide. Combined with lawyers from the top-ranked health law practice, our industry team is a collaborative group composed from critical legal areas vital to a life sciences company including regulatory, transactional, intellectual property, litigation and tax.
About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.